Decoy Therapeutics (DCOY) vs XORTX Therapeutics (XRTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Decoy Therapeutics is the larger company by market cap ($2.0 million vs $1.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DCOY | XRTX |
|---|---|---|
| Share price | $0.8294 | $0.839 |
| Market cap | $1.98M | $1.88M |
| 1-day change | -4.68% | -5.73% |
| P/E ratio (TTM) | 0.03 | — |
| Forward P/E | — | 1.05 |
| EPS (TTM) | $31.19 | $-2.09 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-12.52M | — |
| 52-week high | $16.92 | $3.60 |
| 52-week low | $0.80 | $0.81 |
| Distance from 52-week high | -95.10% | -76.69% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +261.71% | — |
| Average volume | 2.17M | 776.48K |
| Shares outstanding | 2.39M | 2.25M |
| Employees | 11 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Decoy Therapeutics
DCOY stock →Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company.
Health Care · Biotechnology: Pharmaceutical Preparations · 11 employees
About XORTX Therapeutics
XRTX stock →XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney.
Health Care · Biotechnology: Pharmaceutical Preparations
DCOY vs XRTX FAQ
Which is bigger, Decoy Therapeutics or XORTX Therapeutics?
Decoy Therapeutics (DCOY) is larger, with a market capitalization of $1.98M compared with $1.88M for XORTX Therapeutics (XRTX).
Are Decoy Therapeutics and XORTX Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.